KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $107.5 million.

  • Neogenomics' Operating Expenses rose 1184.78% to $107.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $429.1 million, marking a year-over-year increase of 1512.3%. This contributed to the annual value of $382.2 million for FY2024, which is 847.65% up from last year.
  • Latest data reveals that Neogenomics reported Operating Expenses of $107.5 million as of Q3 2025, which was up 1184.78% from $124.9 million recorded in Q2 2025.
  • Neogenomics' 5-year Operating Expenses high stood at $124.9 million for Q2 2025, and its period low was $56.7 million during Q1 2021.
  • In the last 5 years, Neogenomics' Operating Expenses had a median value of $89.8 million in 2023 and averaged $90.5 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 7603.04% in 2021, then tumbled by 416.47% in 2022.
  • Neogenomics' Operating Expenses (Quarter) stood at $86.8 million in 2021, then decreased by 4.16% to $83.2 million in 2022, then grew by 3.55% to $86.2 million in 2023, then increased by 11.02% to $95.7 million in 2024, then increased by 12.34% to $107.5 million in 2025.
  • Its Operating Expenses was $107.5 million in Q3 2025, compared to $124.9 million in Q2 2025 and $101.1 million in Q1 2025.